These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35313441)

  • 1. Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II).
    Nicolosi A; Pellicano R; Caviglia GP
    Minerva Med; 2022 Feb; 113(1):106-108. PubMed ID: 35313441
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
    Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
    Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma abnormal prothrombin (PIVKA-II): a new and reliable marker for the detection of hepatocellular carcinoma.
    Takikawa Y; Suzuki K; Yamazaki K; Goto T; Madarame T; Miura Y; Yoshida T; Kashiwabara T; Sato S
    J Gastroenterol Hepatol; 1992; 7(1):1-6. PubMed ID: 1371940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants.
    Motohara K; Endo F; Matsuda I; Iwamasa T
    J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
    Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
    Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic radiotherapy for hepatocellular carcinoma induced by hepatitis C and the relationships of changes in carbohydrate antigen 19-9 with AFP and PIVKA-II.
    Maebayashi T; Ishibashi N; Aizawa T; Sakaguchi M; Okada M
    Cancer Radiother; 2021 May; 25(3):242-248. PubMed ID: 33455875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of protein induced by absence of vitamin K absence or antagonist II, alpha-fetoprotein and gamma-glutamyltransferase/aspartate aminotransferase ratio for the diagnosis of hepatocellular carcinoma in transplantation candidates.
    Ekmen N; Akalin Ç; Akyildiz M
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):294-299. PubMed ID: 32796360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma.
    Chen J; Tang D; Xu C; Niu Z; Li H; Li Y; Zhang P
    Lab Med; 2021 Jul; 52(4):381-389. PubMed ID: 33159511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.
    Park H; Park JY
    Biomed Res Int; 2013; 2013():310427. PubMed ID: 24455683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients.
    Saitta C; Raffa G; Alibrandi A; Brancatelli S; Lombardo D; Tripodi G; Raimondo G; Pollicino T
    Medicine (Baltimore); 2017 Jun; 96(26):e7266. PubMed ID: 28658121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.